|
|
|
Agenda
18 March 2008
|
8:00 |
Registration
|
|
9:00 |
Conference Chair Welcome Address
Kumar Gadamasetti, President & CEO, Delphian Pharmaceuticals
|
|
9:10 |
Pharma Development and Case Studies
Chaired by Kumar Gadamasetti, President & CEO, Delphian Pharmaceuticals
|
|
9:15 |
Drug Discovery: Key Learning From Recent Success Stories - A Medicinal Chemistry Perspective
Bharat K.Trivedi , CSO, Medicinal Chemistry, Drug Discovery Research, Wockhardt
SAR and pre-clinical strategies that led to the discovery and development of a successful therapeutic agent in a given therapeutic area will be presented along with a perspective on what is essential for Indian pharma to be globally competitive.
|
|
9:55 |
Drug Discovery Alliance Between Ranbaxy and GlaxoSmithKline, a Case History
Pradip Bhatnagar, Sr.VP, New Drug Discovery Research, Ranbaxy Pharmaceuticals
|
|
10:35 |
Coffee break and networking in exhibition hall
|
|
11:20 |
Interaction of Commercial, Discovery and Development: Medicinal Products of Differentiated Value
Kumar Rajinder, President of Research, Development and Commercialization, Dr. Reddy’s Laboratories Ltd
|
|
12:00 |
Green Chemistry Influence in Medicinal Chemistry
Asit K. Chakraborti, Professor and Head of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER)
Scope of green chemistry in drug design will be discussed with reference to develop novel concepts (e.g., demand-based thiolate anion generation, atom-economy in alkylation, water catalysis by electrophile-nucleophile dual activation through cooperative hydrogen bond formation), solvent-free reactions and microwave-assisted synthesis.
|
|
12:30 |
Lunch & networking in exhibition hall followed by poster viewing
|
|
14:00 |
Modelling, SAR and Synthesis
Chaired by Robert A. Volkmann, Senior Research Fellow, Pfizer Global R&D
|
|
14:10 |
Relating Molecular Structure to Biological Activity
Robert A. Volkmann, Senior Research Fellow, Pfizer Global R&D
A strategy for capturing “system-wide” drug-effect information of medicines will be described. The potential application of this method in drug discovery will be illustrated.
|
|
14:50 |
Discovery of Novel Anti-Infectives Through SAR Studies
Uma Ramamchandran, Vice President - Medicinal Chemistry , Orchid Research Laboratories
Orchid Research Laboratories' effort to expand the spectrum of antibacterial activity of the oxazolidinones to include gram-negative organisms has led to the discovery of the novel oxazolidinone scaffold, which has superior in vitro activity, excellent PK profile and comparable in vivo efficacy to Linezolid.
|
|
15:20 |
Coffee break and networking in exhibition hall
|
|
16:00 |
Increasing the Throughput in Microwave Synthesis - Going Parallel
C. Oliver Kappe, Professor of Organic Chemistry, University of Graz
Microwave chemistry can be carried out very efficiently in a parallel format using dedicated rotors or microtiter plate systems. Several hundred reactions can be performed in a single microwave experiment using multimode microwave devices.
|
|
16:30 |
Homogeneous and Heterogeneous Palladium-Mediated Cross-Coupling Reactions Using Controlled Single- and Multi-Mode Microwave Heating
Uwe Schön, Principal Scientist Medicinal Chemistry, Solvay Pharmaceuticals
Different boronic acids and homogeneous and heterogeneous palladium sources under microwave irradiating conditions using single-mode and multi-mode microwave equipment will be compared. Examples of running medicinal chemistry programs will be presented.
|
|
17:00 |
Enabling the Chemists in Pharma Research
K.K.Bhagchandani, Director-Asia Pacific, Advanced Chemistry Development
|
|
17:30 |
Drinks reception sponsored by CombiChem.net |
19 March 2008
|
9:30 |
Target Identification
Chaired by Michael Spiegel, Deputy Director, Monash University
|
|
9:35 |
Ultra High Throughput Monoclonal Antibody Production
Michael Spiegel, Deputy Director, Monash University
The use of custom-made, high-affinity monoclonal antibodies has proven crucial in medicinal chemistry. High-throughput production using patented screening technology and state-of-the-art robotics systems will be discussed.
|
|
10:05 |
A Novel Approach for Identifying Phamacophore Moiety Within Large Biologically Active Natural Products
Hakim Djaballah, Director, HTS Core Facility, Memorial Sloan Kettering Cancer Centre
A novel strategy for identifying critical pharmacophore within active natural products can be employed towards other biologically active natural products to make them more synthetically accessible as potential therapies.
|
|
10:35 |
Coffee break and networking in exhibition hall
|
|
11:00 |
Chiral Conformations and Host Immune Clearance Patterns
Marcella Mascarenhas, Research Scientist-Biologist, Independant Collaborative Research
|
|
11:30 |
BioMEMS Based Target Detection of Heat Shock Protein 90 Interactions
Muthukumaran Packirisamy, Associate Professor and Research Chair, Concordia University
The target identification of Heat Shock Protein 90 (HSP90) interactions through bio-mechanical interactions using a highly sensitive BioMEMS technique that has high specificity and high throughput will be presented.
|
|
12:00 |
Lunch & networking in exhibition hall followed by poster viewing
|
|
13:30 |
Lead Optimisation & Business Partnering
Chaired by Bala Ganesh Tanjore, Head of Research, VP-Discovery, AstraZeneca-India
|
|
13:35 |
Drug Discovery Studies to Treat Tuberculosis
Bala Ganesh Tanjore, Head of Research, VP-Discovery, AstraZeneca-India
|
|
14:05 |
Discovery of IsentressTM, First in Class HIV Integrase Inhibitor for the Treatment of HIV Infection
Vincenzo Summa, Director, Merck-MRL Rome
HIV remains a serious health problem despite the progress obtained with HAART. IsentressTM is the first HIV Integrase inhibitor approved for the treatment of HIV-1 infection, with a completely novel mechanism. Details on its discovery will be presented.
|
|
14:35 |
Coffee Break and Poster Award Ceremony
|
|
15:00 |
String of Pearls: Orchestrating the Best Outcomes from Multiple Partners in Medicinal Chemistry Program
Swami Subramaniam, Head, India Operations and Director, Business Development, Rheosciences A/S
|
|
15:30 |
Discovery of Novel 4-Aminoquinazolines and C-2, C-8 and N-9 Trisubstituted Purines as Potent Aurora-A Kinase Inhibitors
Parthasarathi Das, Research Investigator, Dr. Reddy's Laboratories
The validation of Aurora kinases as a drug target has spawned a flurry of activity over the last few years, directed towards the discovery of novel Aurora kinase inhibitors with potential for anticancer drug therapy.
|
|
16:00 |
Conference Chair Closing Remarks
Kumar Gadamasetti, President & CEO, Delphian Pharmaceuticals |
|